EMA Authorised: Wyost (denosumab) — Sandoz GmbH

View source ↗

Summary

The EMA authorises Wyost (denosumab) by Sandoz GmbH for indications in Giant Cell Tumor of Bone and other bone neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Bone
• Neoplasms of Bone Tissue

Drugs mentioned

• WYOST (Denosumab)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Sandoz GmbH. Decision date: 13/08/2025